Thus, they tried a pan-FGFR inhibitor (BGJ398, infigratinib) with pan-PI3K inhibitors (GDC-0941, BKM 120) in endometrial cancer cell lines, which showed a significant increase in cell death and long-term survival when the PI3K inhibitor was combined with BGJ398 [54]. This evidence concerns the gene PIK3CA and endometrial cancer.